EBITDA: Income before interest, taxes, depreciation and amortization.
Inhibikase Therapeutics, Inc. (IKT) had EBITDA of $-10.81M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-9.92M |
|
-- |
|
-- |
|
$10.83M |
|
$-10.83M |
|
$0.92M |
|
$-9.92M |
|
$-9.92M |
|
$-9.92M |
|
$-9.92M |
|
$-9.92M |
|
$-9.92M |
|
$-10.83M |
|
|
EBITDA |
$-10.81M |
90.01M |
|
90.01M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$88.79M |
|
$0.02M |
|
$0.06M |
|
$88.85M |
|
$8.80M |
|
-- |
|
-- |
|
$8.80M |
|
$80.05M |
|
$80.05M |
|
$80.05M |
|
74.52M |
|
| Cash Flow Statement Financials | |
$-9.68M |
|
$30.90M |
|
$0.03M |
|
$56.49M |
|
$77.74M |
|
$21.25M |
|
$6.25M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.39% |
|
-12.39% |
|
-11.16% |
|
-12.39% |
|
$1.07 |
|
$-0.11 |
|
$-0.11 |
|